Advertisement
Advertisement
VCEL
Vericel Corporation
45.48
USDSponsored
+4.39
+10.68%
Nov 04, 15:59 UTC -5
Closed
Pre-Market
45.48
0.00
-0.01%
Vericel Corporation (VCEL) Earnings
VCEL Earnings Reports
Positive Surprise Ratio
VCEL beat 25 of 43 last estimates.
58%
Next Report
Today BMO
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$79.51M
/$0.05
Implied change from Q2 26 (Revenue/ EPS)
+2.65%
/+25.00%
Implied change from Q3 25 (Revenue/ EPS)
+17.78%
/-50.00%
Vericel Corporation earnings per share and revenue
On Jul 30, 2026, VCEL reported earnings of 0.04 USD per share (EPS) for Q2 26, beating the estimate of -0.02 USD, resulting in a 239.37% surprise. Revenue reached 77.46 million, compared to an expected 74.14 million, with a 4.47% difference. The market reacted with a +2.12% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 79.51 million USD, implying an increase of 25.00% EPS, and increase of 2.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$1.48
Actual
-$1.37
Surprise
+7.82%
Arcutis Biotherapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.16
Actual
$0.06
Surprise
-64.54%
Viridian Therapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.81
Surprise
+18.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
Vir Biotechnology, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.76
Actual
-$0.56
Surprise
+25.20%
Revolution Medicines, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$2.46
Actual
-$1.90
Surprise
+22.81%
Bio-Rad Laboratories, Inc. Class B
Report Date
Nov 04, 2026 For Q3 26
Estimate
$2.24
Actual
$2.65
Surprise
+17.92%
Nuvation Bio Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.12
Actual
-$0.12
Surprise
+4.15%
Myriad Genetics Inc
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+46.08%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were Vericel Corporation's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Vericel Corporation reported EPS of $0.04, beating estimates by 239.37%, and revenue of $77.46M, 4.47% above expectations.
How did the market react to Vericel Corporation's Q2 2026 earnings?
The stock price moved up 2.12%, changed from $46.62 before the earnings release to $47.61 the day after.
When is Vericel Corporation expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Vericel Corporation's next earnings report?
Based on 8
analysts, Vericel Corporation is expected to report EPS of $0.05 and revenue of $79.51M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.